Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Sinopharm Group Co ( (HK:1099) ) is now available.
Sinopharm subsidiary China National Medical Device Co. Ltd. reported modest top-line growth for the three months ended 31 March 2026, with revenue rising 1.23% year on year to RMB 16.999 billion and total assets up 3.82%. However, operating profit fell 20.41%, comprehensive income attributable to the parent slipped 7.47%, and operating cash flow turned more negative, suggesting rising cost pressures and weaker profitability despite balance-sheet expansion.
Equity attributable to the parent’s owners edged up 1.39%, indicating some strengthening of the capital base even as earnings softened in the period. The combination of slower profit growth, deteriorating cash flow and asset expansion may raise questions for investors about margin sustainability and working-capital efficiency in Sinopharm’s medical device segment, an important contributor to the group’s broader healthcare portfolio.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a major Chinese healthcare conglomerate focused on pharmaceutical distribution and medical device supply through subsidiaries such as China National Medical Device Co. Ltd. The group serves hospital, clinical and wider medical markets across China, leveraging its scale to provide medicines, medical equipment and related services nationwide.
Average Trading Volume: 5,648,982
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$63.29B
For detailed information about 1099 stock, go to TipRanks’ Stock Analysis page.